For patients with a new synthetic arteriovenous graft for hemodialysis vascular access, taking fish oil every day led to a mix of negative and positive results, a randomized trial showed.
Covidien (NYSE: COV), el proveedor líder global de productos para la salud, anunció hoy que los resultados del uso de su stent EverFlex™ realizados durante un año para la implantación del stent en la arteria femoral superficial (AFS) fueron presentados durante la Conferencia de International Symposium on Endovascular Therapy (Simposio Internacional de Terapias Endovasculares), (ISET, por sus siglas en inglés).
According to a single-center study published in the Journal of Vascular Surgery, mortality is significantly greater for females undergoing elective endovascular repair (EVAR) for abdominal aortic aneurysms (AAA) than for males (2012;55:906–913). The study also showed that colon ischemia, native arterial rupture, and type 1 endoleaks are more frequent in women than in men. Elective EVAR benefits men more than women, concluded Manish Mehta, MD, et al, from the Vascular Group at the Albany Medical Center in Albany, New York.
The Society for Vascular Surgery and the American Venous Forum have issued clinical practice guidelines for early thrombus removal strategies in acute deep venous thrombosis (DVT). The guidelines, which were drafted by Mark H. Meissner, MD, et al, were published April 2 online ahead of print in the Journal of Vascular Surgery.
An evaluation of the comparative effectiveness of carotid revascularization procedures stratified by Medicare age was published March 30 online ahead of print in the Journal of Vascular Surgery by Jeffrey Jim, MD, et al for the Society for Vascular Surgery (SVS) Outcomes Committee.
For older patients, endovascular repair of an abdominal aortic aneurysm (AAA) offers long-term survival advantages over open repair, researchers found. Among patients ages 65 and up, traditional surgical repair was associated with significantly higher risks of both all-cause and AAA-related death over a mean of about 2.5 years (P=0.01 and P<0.001, respectively), Rubie Sue Jackson, MD, MPH, of Georgetown University Hospital, and colleagues reported in the April 18 issue of the Journal of the American Medical Association.
Medtronic, Inc. (Minneapolis, MN) announced that it will be commencing the IN.PACT Global superficial femoral artery (SFA) clinical study. The international, prospective, multicenter study will collect and assess safety and efficacy data on the company’s In.Pact Admiral paclitaxel drug-eluting balloon (DEB) for the treatment of atherosclerotic disease in the SFA and/or popliteal arteries.
Una nueva investigación a largo plazo sugiere ahora que el uso de dilatadores totalmente biodegradables es seguro para las arterias del corazón. En un informe que aparece en la edición del 16 de abril de la revista Circulation, investigadores japoneses dijeron que un estudio de diez años ha mostrado que el dilatador biodegradable Igaki-Tamai, fabricado con un material basado en la fécula de maíz, se disuelve en la pared arterial, sin dejar material foráneo permanente en una arteria y reduciendo la ocurrencia de un coágulo sanguíneo dentro del dilatador.
Stryker’s Sustainability Solutions division has announced the launch of Restep, a compression sleeve for deep vein thrombosis treatment.
On Sunday evening, CX 34 delegates heard the results of the world’s first multicentre, randomised, controlled trial that compared EVAR and open repair for ruptured abdominal aortic aneurysms. The Dutch AJAX trial results demonstrated no difference between EVAR and open repair in emergent cases. In the same session, the audience also heard an outline of the SWIFT study on the effect of transport on ruptured aneurysm treatment outcomes. While AJAX results shed some light on treatment for ruptured aneurysms, many questions still remain unanswered
On Monday, CX delegates heard early data on the multilayer stent. In the discussion it became apparent that MARS requires firm thrombosis in the multilayers and flow to occur into the branches. The indicator of success is the reduction of sac diameter and the consensus was not to use the device in ruptured aneurysms. It became clear that the many experts cautioned not to expect too much of the device and to restrict its use in those high-risk patients where there is no other option.
In May 2012, Medtronic will initiate the IN.PACT Global SFA Trial, a single arm, real-world study of the IN.PACT Admiral drug-eluting balloon (DEB) for revascularisation of femoral-popliteal arteries in patients with claudication and rest pain. The study will be part of the company’s drug-eluting balloon programme which already includes eight registries and 10 randomised controlled trials.
Matt Bown, Leicester, UK, led an international team of investigators which identified a single gene that is linked to the development of abdominal aortic aneurysm. During the discussion session, after the results were presented, the point was made that the interaction between the gene LRP1 and environmental factors was key.
Preliminary results from eight patients within the 12-month follow-up window of the PACIFIER trial showed significantly lower target lesion revacularisation was needed for patients in the drug-eluting balloon group vs the percutaneous transluminal angioplasty group. Similarly six-month follow-up from FREEWAY demonstrated a lower target lesion revascularisation rate after Freeway drug-eluting balloon and stent than after plain old balloon angioplasty and stent.
The first-in-man experience results with a new bioresorbable scaffold for superficial femoral artery lesions were presented by Andrew Holden, Auckland, New Zealand, yesterday. Holden described the Stanza Bioresorbable Scaffold System from 480 Biomedical and initial case experience from the first patients treated in the STANCE trial.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos